The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Cytosorbents Corporation shares valued at $3,600 were purchased by Capponi Vincent on Jun 21. At $1.80 per share, Capponi Vincent acquired 2,000 shares. The insider’s holdings grew to 443,545 shares worth approximately $0.92 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Also, Chan Phillip P. purchased 2,221 shares, netting a total of over 4,109 in proceeds. Following the buying of shares at $1.85 each, the insider now holds 768,351 shares.
Before that, Capponi Vincent had added 3,000 shares to its account. In a trade valued at $6,000, the insider bought Cytosorbents Corporation shares for $2.00 each. Upon closing the transaction, the insider’s holdings increased to 3,000 shares, worth approximately $0.91 million.
As published in a research note from William Blair on May 26, 2022, Nutanix Inc. [NTNX] has been rated down from an Outperform to a Mkt perform. Analysts at BofA Securities downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in late May. As of January 19, 2022, KeyBanc Capital Markets has initiated its “an Overweight” rating for NTNX. Earlier on September 02, 2021, Needham resumed its rating. Their recommendation was “a Buy” for NTNX stock. This represents a 79.3% premium over Wednesday’s closing price. Analysts at Jefferies started covering the stock with ‘”a Buy”‘ outlook in a report released in mid September. As of September 01, 2020, SVB Leerink has initiated its “an Outperform” rating for CTSO. Earlier on August 08, 2017, Maxim Group resumed its rating. Their recommendation was “a Buy” for CTSO stock.
Analyzing CTSO’s Price Performance
On Wednesday, Cytosorbents Corporation [NASDAQ: CTSO] rose 17.61% to $2.07. The stock’s lowest price that day was $1.7169, but it reached a high of $2.09 in the same session. During the last five days, there has been a drop of approximately -8.81%. Over the course of the year, Cytosorbents Corporation shares have dropped approximately -50.60%. Shares of the company reached a 52-week high of $4.3300 on 01/04/22 and a 52-week low of $1.6900 on 06/21/22. A 50-day SMA is recorded $2.2100, while a 200-day SMA reached $4.3100. Nevertheless, trading volume fell to 0.52 million shares from 0.41 million shares the previous day.
Support And Resistance Levels for Cytosorbents Corporation (CTSO)
According to the 24-hour chart, there is a support level at 1.8300, which, if violated, would cause prices to drop to 1.5900. In the upper region, resistance lies at 2.2000. The next price resistance is at 2.3300. RSI (Relative Strength Index) is 49.31 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.1700, which suggests the price will decrease in the coming days. Percent R is at 60.42%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Cytosorbents Corporation subject to short interest?
Stocks of Cytosorbents Corporation saw a sharp rise in short interest on Apr 28, 2022 jumping by 0.22 million shares to 2.05 million. Data from Yahoo Finance shows that the short interest on Mar 30, 2022 was 1.83 million shares. A jump of 10.73% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 9.56 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.56.
Which companies own the most shares of Cytosorbents Corporation (CTSO)?
According to BlackRock Fund Advisors filings, the company currently owns 2,394,443 shares, which is about 5.50% of the total CTSO shares outstanding. The investor’s shares have plunged by -26,599 from its previous 13-F filing of 2421042.0 shares. With the completion of the buy, Avenir Corp.’s stake is now worth $4,200,662. Skylands Capital LLC acquire a 9.33% interest valued at $4.11 million while The Vanguard Group, Inc. sold a -7,244 stake. A total of -4,256 shares of Cytosorbents Corporation were sold by Neuberger Berman Investment Advis during the quarter, and 110,321 were bought by Granahan Investment Management, L. In its current portfolio, Sargent Investment Group LLC holds 827,380 shares valued at $1.6 million.
In terms of Cytosorbents Corporation share price expectations, FactSet research, analysts set an average price target of $8.20 in the next 12 months, up nearly 411.36% from the previous closing price of $1.76. Analysts anticipate Cytosorbents Corporation stock to reach $9.00 by 2022, with the lowest price target being $6.00. In spite of this, 5 analysts ranked Cytosorbents Corporation stock as a Buy at the end of 2022.